Hims & Hers Health, Inc. (NYSE:HIMS) Insider Michael Chi Sells 7,259 Shares

Hims & Hers Health, Inc. (NYSE:HIMS) insider Michael Chi sold 7,259 shares of the company’s stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $32.25, for a total value of $234,102.75. Following the completion of the sale, the insider now owns 184,947 shares in the company, valued at approximately $5,964,540.75. This represents a 3.78 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Michael Chi also recently made the following trade(s):

• On Monday, December 2nd, Michael Chi sold 2,054 shares of Hims & Hers Health stock. The shares were sold at an average price of $33.56, for a total value of $68,932.24.
• On Friday, October 25th, Michael Chi sold 17,304 shares of Hims & Hers Health stock. The stock was sold at an average price of $22.00, for a total transaction of $380,688.00.
• On Monday, October 21st, Michael Chi sold 7,500 shares of Hims & Hers Health stock. The shares were sold at an average price of $22.20, for a total transaction of $166,500.00.

Hims & Hers Health Stock Down 0.3 %

NYSE:HIMS opened at $30.01 on Friday. The stock’s fifty day simple moving average is $24.78 and its 200-day simple moving average is $20.96. The firm has a market capitalization of $6.56 billion, a P/E ratio of 68.20 and a beta of 1.25. Hims & Hers Health, Inc. has a 12-month low of $8.09 and a 12-month high of $35.02.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.26. The company had revenue of $401.56 million during the quarter, compared to analyst estimates of $382.20 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The company’s revenue for the quarter was up 77.1% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.04) EPS. As a group, equities research analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Hedge Funds Weigh In On Hims & Hers Health

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Quest Partners LLC increased its position in shares of Hims & Hers Health by 22.6% in the 3rd quarter. Quest Partners LLC now owns 4,373 shares of the company’s stock valued at $81,000 after buying an additional 807 shares in the last quarter. CWM LLC raised its position in shares of Hims & Hers Health by 21.4% during the third quarter. CWM LLC now owns 5,982 shares of the company’s stock worth $110,000 after purchasing an additional 1,054 shares during the period. Arizona State Retirement System lifted its holdings in shares of Hims & Hers Health by 3.0% during the 2nd quarter. Arizona State Retirement System now owns 40,344 shares of the company’s stock valued at $815,000 after purchasing an additional 1,173 shares in the last quarter. Victory Capital Management Inc. grew its position in shares of Hims & Hers Health by 6.6% in the 2nd quarter. Victory Capital Management Inc. now owns 19,469 shares of the company’s stock valued at $393,000 after purchasing an additional 1,212 shares during the period. Finally, Nisa Investment Advisors LLC increased its stake in Hims & Hers Health by 679.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock worth $37,000 after purchasing an additional 1,603 shares in the last quarter. 63.52% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several analysts have recently weighed in on HIMS shares. Needham & Company LLC assumed coverage on shares of Hims & Hers Health in a report on Thursday, August 22nd. They set a “buy” rating and a $24.00 price objective for the company. TD Cowen reissued a “buy” rating and issued a $28.00 price objective on shares of Hims & Hers Health in a research note on Wednesday, November 20th. Piper Sandler restated a “neutral” rating and issued a $21.00 target price (up from $18.00) on shares of Hims & Hers Health in a research note on Tuesday, November 5th. Canaccord Genuity Group upped their price target on shares of Hims & Hers Health from $28.00 to $38.00 and gave the stock a “buy” rating in a research report on Monday, December 2nd. Finally, Deutsche Bank Aktiengesellschaft raised their price objective on shares of Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a research report on Wednesday, November 6th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $21.43.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.